The researchers have always stated that COX-2 inhibitors are needed not only in the non-steroidal anti-inflammatory drugs (NSAIDs) area but also in other therapeutic applications, including prevention of cancer and Alzheimer's disease (AD) (Abdellatif et al., 2022, Ayman et al., 2023, Chen et al., 2023, Kumar et al., 2023, Moussa et al., 2021). This evidence concerns the gene PTGS2 and early-onset autosomal dominant Alzheimer disease.